Chronic activation of the innate immune system may underlie the metabolic syndrome
Keywords:
Inflammation, Cytokines, Non-insulin dependent diabetes mellitus, Cardiovascular disease, Obesity, Syndrome XAbstract
CONTEXTO: The metabolic syndrome is characterized by a clustering, in free-living populations, of cardiovascular and diabetes risk factors generally linked to insulin resistance, obesity and central obesity. Consonant with the well-established inflammatory pathogenesis of atherosclerotic disease, the metabolic syndrome is now being investigated in relation to its inflammatory nature. OBJETIVO: We present cross-sectional findings demonstrating that markers of inflammation correlate with components of the metabolic syndrome, and prospective findings of the ARIC Study indicating that markers of inflammation and endothelial dysfunction predict the development of diabetes mellitus and weight gain in adults. We present biological evidence to suggest that chronic activation of the innate immune system may underlie the metabolic syndrome, characterizing the common soil for the causality of type 2 diabetes mellitus and cardiovascular disease. CONCLUSIONS: Better understanding of the role of the innate immune system in these diseases may lead to important advances in the prediction and management of diabetes and cardiovascular disease.
Downloads
References
Stern MP. Diabetes and cardiovascular disease. The “common soil” hypothesis. Diabetes 1995;44(4):369-74.
Reaven GM. Banting Lecture 1988: role of insulin resistance in hu- man disease. Diabetes 1988;37:1595-607.
DeFronzo RA, Ferranini E. Insulin Resistance: a multifaceted syn- drome responsible for NIDDM, obesity, hypertension, dyslipidemia, and other atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
Alberti KGMM, Zimmet PZ, for the WHO Consultation. Defini- tion, diagnosis and classification of diabetes mellitus and its compli- cations. Part 1: Diagnosis and classification of diabetes mellitus, pro- visional report of a WHO consultation. Diabet Med 1998;15:539- 53.
Schmidt MI, Watson RL, Duncan BB, Metcalf P, Brancati FL, Sharrett AR, Davis CE, Heiss G, for the ARIC Investigators. Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its as- sociation with fasting insulin and central and overall obesity in a general population. Metabolism 1996;45(6):699-706.
Zimmet PZ, Collins VR, Dowse GK, et al. Is hyperinsulinemia a central characteristic of a chronic cardiovascular risk factor clustering syndrome? Mixed findings in Asian Indian, Creole and Chinese Mauritians. Mauritius Non-communicable Disease Study Group. Diabet Med 1994;11(4):388-96.
Schmidt MI, Duncan BB, Watson RL, Sharrett AR, Brancati FL, Heiss G. A metabolic syndrome in whites and African-Americans: the Atherosclerosis Risk in Communities baseline study. Diabetes Care 1996;19(5):414-8.
Ross R. Atherosclerosis: an inflammatory disease. New Engl J Med 1999;340(2):115-26.
Lindberg G, Lundblad A, Gullberg B, Nilsson-Ehle P, Hanson BS. Serum total sialic acid and sialoprotein concentration in relation to coronary heart disease risk markers. Atherosclerosis 1993;103:123-9.
Lindberg G, Eklund GA, Bullberg B, Rastam L. Serum sialic acid concentration and cardiovascular mortality. BMJ 1991;302:143-6.
Ridker PM. Evaluating novel cardiovascular risk factors: Can we bet- ter predict heart attacks? Ann Intern Med 1999;130:933-7.
Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med 2000;133(2):81-91.
Duncan BB, Schmidt MI, Offenbacher S, Wu KK, Savage PJ, Heiss G. Factor VIII and other hemostasis variables are related to incident diabetes in adults: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 1999;22(5):767-72.
Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflam- mation and prediction of diabetes mellitus in adults (Atherosclero- sis Risk in Communities study): a cohort study. Lancet 1999;353:1649-52.
Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a dis- ease of the innate immune system: association of acute-phase reac- tants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40:1286-92.
Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. C-reactive pro- tein in healthy subjects: association with obesity, insulin resistance, and endothelial dysfunction. Arterioscler Thromb Vasc Biol 1999;19:972-8.
FestaA, D’Agostino RB, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resist- ance syndrome. The Insulin ResistanceAtherosclerosisStudy (IRAS). Circulation 2000;201:42-7.
Morange PE,Alessi MC, Verdier M, Casanova D, Magalon G, Juhan- Vague I. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level.Arterioscler Thromb VascBiol 1999;19(5):1361- 5.
Funahashi T, Nakamura T, Shimomura K, Maeda K, Kuriyama H, Takahashi M, AritaY, Kihara S, MatsuzawaY. Role ofadipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 1999;38:202-6.
Mohamed-AliV, GoodrickS, Rawesh A, Katz DR, Miles JM,Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997;82(12):4196-200.
Duncan BB, Schmidt MI, Chambless LE, Folsom AR, Carpenter M, Heiss G, for the ARIC Investigators. Fibrinogen, other putative markers of inflammation and weight gain in middle-aged adults. The ARIC Study. Obesity Res 2000;8(4):279-86.
Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998;41(10):1241-8.
Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996;272:50-3.
Memon RA, Feingold KR, Grunfeld C. Cytokines and intermedi- ary metabolism. In: Remick DG, Friedland JS, editors. Cytokines in health and disease. 2nd edition. NewYork: Marcel Dekker; 1997:381- 99.
Kushner I, Mackiewicz A. The acute phase response: an overview. In: Mackiewicz A, Kushner I, Baumann H, editors. Acute Phase Proteins: Molecular Biology, Biochemistry, and ClinicalApplications. Boca Raton: CRC Press; 1993:4-19.
Bjorntorp P, Rosmond R. The metabolic syndrome: a neuroendo- crine disorder? Br J Nutr 2000;83(Suppl 1):S49-S57.
Bjorntorp P, Rosmond R. Neuroendocrine abnormalities in visceral obesity. Int J Obes Relat Metab Disord 2000;24(Suppl 2):S80-S85.
Reichlin S. Neuroendocrinology. In: Reichlin S, Wilson JD, Foster DW, Kronenberg HM, Larsen PR, editors. Williams Text- book of Endocrinology. 9th ed. Philadelphia: WB Saunders Co.; 1998:165-248.
Hotamisligil GS. Mechanisms of TNF-a induced insulin resistance. Exp Clin Endocrinol Diabetes 1999;107:119-25.
Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 2000;181(Suppl 3):S462-S472.
Campos SP, Baumann H. Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes. Molec Cell Biol 1992;12(4):1789-992.
Melidonis A, Stefanidis A, Tournis S, et al. The role of strict meta- bolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients. Clin Cardiol 2000;23(3):160-4.
Ceriello A. Hyperglycemia: the bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications. Diabetes Nutr Metab 1999;12(1):42-6.
